原著 |
|
|
|
|
高表达过氧化物酶体增殖子激活受体γ诱导小鼠原代肝细胞发生脂肪变性 |
白亮1,2, 张亚莉1,2, 谢晨1,2, 王蓉1,2, 赵四海1,2, 贾玉枝3, 刘恩岐1,2 |
1. 西安交通大学医学部心血管中心动脉粥样硬化与脂代谢研究室, 陕西 西安 710061;
2. 西安交通大学医学部医学实验动物中心, 陕西 西安 710061;
3. Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA |
|
Overexpression of PPARγ induces adipogenic steatosis in mouse primary hepatocytes |
BAI Liang1,2, ZHANG Yali1,2, XIE Chen1,2, WANG Rong1,2, ZHAO Sihai1,2, JIA Yuzhi3, LIU Enqi1,2 |
1. Research Institute of Atherosclerotic Disease, Xi'an Jiaotong University School of Medicine, Xi'an 710061, China;
2. Laboratory Animal Center, Xi'an Jiaotong University School of Medicine, Xi'an 710061, China;
3. Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA |
引用本文:
白亮 等. 高表达过氧化物酶体增殖子激活受体γ诱导小鼠原代肝细胞发生脂肪变性[J]. 浙江大学学报(医学版), 2016, 45(1): 68-74.
BAI Liang, ZHANG Yali, XIE Chen, WANG Rong, ZHAO Sihai, JIA Yuzhi, LIU Enqi. Overexpression of PPARγ induces adipogenic steatosis in mouse primary hepatocytes. Journal of ZheJiang University(Medical Science), 2016, 45(1): 68-74.
链接本文:
http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2016.01.11
或
http://www.zjujournals.com/xueshu/med/CN/Y2016/V45/I1/68
|
[1] |
ANDERSON N, BORLAK J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis[J]. Pharmacol Rev, 2008, 60(3):311-357.
|
[2] |
REDDY J K, RAO M S. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 290(5):G852-G858.
|
[3] |
BOPPIDI H, DARAM S R. Nonalcoholic fatty liver disease:hepatic manifestation of obesity and the metabolic syndrome[J]. Postgrad Med, 2008, 120(2):E01-E07.
|
[4] |
JIA Y, VISWAKARMA N, REDDY J K. Med1 subunit of the mediator complex in nuclear receptor-regulated energy metabolism, liver regeneration, and hepatocarcinogenesis[J]. Gene Expr, 2014, 16(2):63-75.
|
[5] |
REDDY J K, GUO D, JIA Y, et al. Nuclear receptor transcriptional coactivators in development and metabolism[J]. Adv Dev Biol, 2006, 16:389-420.
|
[6] |
SHAO X, WANG M, WEI X, et al. Peroxisome proliferator-activated receptor-gamma:master regulator of adipogenesis and obesity[J]. Curr Stem Cell Res Ther, 2015.Epub ahead of print.
|
[7] |
TONTONOZ P, HU E, SPIEGELMAN B M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor[J]. Cell, 1994, 79(7):1147-1156.
|
[8] |
COSTET P, LEGENDRE C, MORE J, et al. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis[J]. J Biol Chem, 1998, 273(45):29577-29585.
|
[9] |
MEMON R A, TECOTT L H, NONOGAKI K, et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity:troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice[J]. Endocrinology, 2000, 141(11):4021-4031.
|
[10] |
GAVRILOVA O, HALUZIK M, MATSUSUE K, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass[J]. J Biol Chem, 2003, 278(36):34268-34276.
|
[11] |
BAI L, JIA Y, VISWAKARMA N, et al. Transcription coactivator mediator subunit MED1 is required for the development of fatty liver in the mouse[J]. Hepatology, 2011, 53(4):1164-1174.
|
[12] |
WANG Y X. PPARs:diverse regulators in energy metabolism and metabolic diseases[J]. Cell Res, 2010, 20(2):124-137.
|
[13] |
ROSEN E D, SARRAF P, TROY A E, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro[J]. Mol Cell, 1999, 4(4):611-617.
|
[14] |
BARAK Y, NELSON M C, ONG E S, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development[J]. Mol Cell, 1999, 4(4):585-595.
|
[15] |
MATSUSUE K, HALUZIK M, LAMBERT G, et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes[J]. J Clin Invest, 2003, 111(5):737-747.
|
[16] |
WANG Y X, LEE C H, TIEP S, et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity[J]. Cell, 2003, 113(2):159-170.
|
[17] |
YU S, VISWAKARMA N, BATRA S K, et al. Identification of promethin and PGLP as two novel up-regulated genes in PPARgamma1-induced adipogenic mouse liver[J]. Biochimie, 2004, 86(11):743-761.
|
[18] |
WOLINS N E, QUAYNOR B K, SKINNER J R, et al. OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization[J]. Diabetes, 2006, 55(12):3418-3428.
|
[19] |
HALL A M, BRUNT E M, CHEN Z, et al. Dynamic and differential regulation of proteins that coat lipid droplets in fatty liver dystrophic mice[J]. J Lipid Res, 2010, 51(3):554-563.
|
[20] |
HUANG J, IQBAL J, SAHA P K, et al. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver[J]. Hepatology, 2007, 46(1):147-157.
|
[21] |
BADMAN M K, KOESTER A, FLIER J S, et al. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis[J]. Endocrinology, 2009, 150(11):4931-4940.
|
[22] |
XU J, LLOYD D J, HALE C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice[J]. Diabetes, 2009, 58(1):250-259.
|
[23] |
Díez J J, IGLESIAS P. The role of the novel adipocyte-derived hormone adiponectin in human disease[J]. Eur J Endocrinol, 2003, 148(3):293-300.
|
[24] |
BAUCHE I B, EL MKADEM S A, POTTIER A M, et al. Overexpression of adiponectin targeted to adipose tissue in transgenic mice:impaired adipocyte differentiation[J]. Endocrinology, 2007, 148(4):1539-1549.
|
[25] |
UKKOLA O, SANTANIEMI M. Adiponectin:a link between excess adiposity and associated comorbidities?[J]. J Mol Med (Berl), 2002, 80(11):696-702.
|
[26] |
RENALDI O, PRAMONO B, SINORITA H, et al. Hypoadiponectinemia:a risk factor for metabolic syndrome[J]. Acta Med Indones, 2009, 41(1):20-24.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|